Zenas Biopharma (ZBIO) closed at $23.85 on November 20, 2026, down 4.8% from the previous close, on volume of 557,689 shares (30-day average 486,668).
Data as of November 20, 2026.
20-Nov-2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 18-Nov 4:15 PM ET)
Globe Newswire (Tue, 17-Nov 7:00 AM ET)
Zenas BioPharma to Present at the Jefferies London Global Healthcare Conference
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Zenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Zenas BioPharma highlights new-hire equity incentives with 74,900 RSUs tied to four-year retention
Market Chameleon (Mon, 19-Oct 7:37 AM ET)
Globe Newswire (Mon, 12-Oct 7:00 AM ET)
Globe Newswire (Wed, 7-Oct 7:05 AM ET)
Zenas BioPharma to Host Virtual R&D Event
Globe Newswire (Tue, 6-Oct 7:05 AM ET)
Globe Newswire (Tue, 22-Sep 7:05 AM ET)
Zenas BioPharma spotlights hiring momentum with 152,600-share inducement equity grants
Market Chameleon (Mon, 21-Sep 7:35 AM ET)
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Zenas Biopharma trades on the NASDAQ stock market under the symbol ZBIO.
As of November 20, 2026, ZBIO stock price declined to $23.85 with 557,689 million shares trading.
ZBIO has a beta of 0.59, meaning it tends to be less sensitive to market movements. ZBIO has a correlation of 0.01 to the broad based SPY ETF.
ZBIO has a market cap of $1.55 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that ZBIO belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
ZBIO has underperformed the market in the last year with a price return of -31.5% while the SPY ETF gained +6.9%. ZBIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -24.6% and -15.6%, respectively, while the SPY returned -9.3% and -6.2%, respectively.
ZBIO support price is $23.94 and resistance is $26.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZBIO shares will trade within this expected range on the day.